KRAS and non-small cell lung carcinoma: In particular, tumors with LKB1 mutations, which are detected in 15–30% of NSCLC, including tumors with co-occurring KRAS mutations detected in 5–10% of NSCLC [8, 9], unfortunately lack effective targeted therapies and are associated with the resistance to immunotherapy [6].